Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

Pharmacy Team Combats COVID-19 in NYC: Q&A with Mark J. Sinnett, PharmD, FASHP

Mary Choy, PharmD, BCGP, FASHP  |  May 1, 2020

The outbreak of the SARS-CoV-2 virus is disrupting patient care all over the world. In the U.S., many providers have had to adapt to new social distancing measures to care for patients, but struggles remain. Mark J. Sinnett, PharmD, FASHP, director of clinical and educational pharmacy services and director of the Center for Pharmacotherapy Research…

Filed under:Drug UpdatesProfessional Topics Tagged with:Association of Rheumatology Professionals (ARP)coronavirusCOVID-19Hydroxychloroquine (HCQ)pharmacysarilumabtocilizumab

Adapting Care for Pediatric Patients & Parents During the Pandemic: Q&A with Sangeeta Sule, MD, PhD

Susan Bernstein  |  May 1, 2020

Social distancing and telemedicine are creating unique challenges for pediatric rheumatologists to care for their patients—many of whom are 5 years old or younger. Sangeeta Sule, MD, PhD, discusses how her clinic is adapting…

Filed under:Conditions

Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients

Saumya Joseph  |  April 27, 2020

(Reuters)—On April 27, Regeneron Pharmaceuticals Inc. and Sanofi SA said on Monday that their arthritis drug sarilumab (Kevzara) may only help the sickest patients with COVID-19, dampening hopes that the therapy could potentially reach a larger pool of patients with the disease. The drugmakers said they would test high doses of sarilumab only in critically…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19sarilumabtocilizumab

The COVID-19 Pandemic: What You Should Know

Jason Liebowitz, MD, FACR  |  April 20, 2020

Two rheumatologists offer advice on patient management during the COVID-19 pandemic.

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:COVID-19

New Processes May Stick Around After the Pandemic: Q&A with Wendy Ramey, BSPharm, RPh, CSP

Susan Bernstein  |  April 13, 2020

How are COVID-19 and physical distancing restrictions at work affecting rheumatology professionals? The Rheumatologist interviewed clinical pharmacist Wendy Ramey, BSPharm, RPh, CSP, to discuss how the pandemic has changed the way her staff supports rheumatologists at the University of Kentucky Specialty Pharmacy and Infusion Services, Lexington. Ms. Ramey describes how these unprecedented times affect patients,…

Filed under:Practice Support Tagged with:coronavirusCOVID-19Hydroxychloroquine (HCQ)MedicationpharmacistsarilumabTechnologytelemedicinetocilizumab

2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

Luis A. Marcos, MD, MPH, Saika Sharmeen, DO, Jaime Gonzalez, MD, Qingping Yao, MD, PhD, Bettina Fries, MD, & Jack Fuhrer, MD  |  April 13, 2020

In March 2020, an elderly married couple living on Long Island, N.Y., presented to our emergency department with symptoms suspicious for COVID-19 infection. The wife, a-76-year-old woman, presented with complaints of subjective fevers, minimal dry cough and headaches of one-week duration. She denied having any chills, rhinorrhea, diarrhea, abdominal pain or shortness of breath. Two…

Filed under:Conditions Tagged with:COVID-19

No Evidence to Support Biologic Switching Guidelines for JIA

Marilynn Larkin  |  April 1, 2020

NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…

Filed under:ConditionsOther Rheumatic ConditionsPediatric Conditions Tagged with:BiologicsJIAjuvenile idiopathic arthritis (JIA)Pediatric

Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients

Reuters Staff  |  March 25, 2020

March 23 (Reuters)—Roche Holding AG said on Monday it has received the U.S. Food and Drug Administration‘s clearance to test its rheumatoid arthritis treatment on patients hospitalized with severe pneumonia caused by the coronavirus. The company said it was beginning a late-stage study to test the drug in what would be the first well-controlled study…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19FDAtocilizumabU.S. Food and Drug Administration (FDA)

Sarilumab Investigated to Treat COVID-19

Michele B. Kaufman, PharmD, BCGP  |  March 23, 2020

A study investigating sarilumab’s effects on patients with COVID-19 has begun in New York. The treatment blocks IL-6, which may play a role in the respiratory distress caused by the virus…

Filed under:Drug Updates Tagged with:clinical trialsCOVID-19sarilumab

Enemy at the Gates: The Emerging Threat of COVID-19

Philip Seo, MD, MHS  |  March 23, 2020

On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

Filed under:ConditionsOpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:COVID-19Philip SeoRheuminationsSeo

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences